# hyperphosphatemia in patients with chronic kidney disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hyperphosphatemia-in-patients-with-chronic-kidney-disease

> No upcoming FDA catalysts in hyperphosphatemia in patients with chronic kidney disease; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 3, 2024 | [Oxylanthanum NDA/BLA submission](https://sec-api.dev/pdufa/oxylanthanum) | UNCY | hyperphosphatemia in patients with chronic kidney disease | completed | "On September 3, 2024, we submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1766140/000121390024097118/ea0220114-10q_unicycive.htm)) |
| June 30, 2025 | [Oxylanthanum complete response letter (CRL)](https://sec-api.dev/pdufa/oxylanthanum) | UNCY | Hyperphosphatemia in Patients with Chronic Kidney Disease | completed, complete response letter | "Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025059303/ea024746901ex99-1_unicycive.htm)) |

## Drugs

- [Oxylanthanum](https://sec-api.dev/pdufa/oxylanthanum) (UNCY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hyperphosphatemia-in-patients-with-chronic-kidney-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "hyperphosphatemia in patients with chronic kidney disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hyperphosphatemia-in-patients-with-chronic-kidney-disease

```bibtex
@misc{secapidev_indications_hyperphosphatemia_in_patients_with_chronic_kidney_disease_20261116,
  title        = {hyperphosphatemia in patients with chronic kidney disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hyperphosphatemia-in-patients-with-chronic-kidney-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hyperphosphatemia_in_patients_with_chronic_kidney_disease_20261116","title":"hyperphosphatemia in patients with chronic kidney disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hyperphosphatemia-in-patients-with-chronic-kidney-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
